Edetic Acid

Edetic Acid

SCHEMBL6037203

O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.[Zn]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.93
▸ EYA2 O00167 1/20 0.93
▸ APP P05067 1/20 0.93
▸ ACE P12821 1/20 0.93
▸ BLM P54132 2/20 0.88
▸ PMP22 Q01453 2/20 0.88
▸ TSHR P16473 2/20 0.88
▸ KDM4E B2RXH2 2/20 0.88
▸ ALOX15 P16050 2/20 0.88
▸ LMNA P02545 1/20 0.88
▸ CHRM2 P08172 1/20 0.88
▸ ADRA2A P08913 1/20 0.88
▸ DRD1 P21728 1/20 0.88
▸ SLC6A2 P23975 1/20 0.88
▸ SLC6A4 P31645 1/20 0.88
▸ CYP2C19 P33261 1/20 0.88
▸ ADRA1A P35348 1/20 0.88
▸ DRD3 P35462 1/20 0.88
▸ SLC6A3 Q01959 1/20 0.88
▸ HRH3 Q9Y5N1 1/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Edetic Acid SCHEMBL424997 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL8408184 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL4336047 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL21483279 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL4956650 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL15653891 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL4637550 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL20920103 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL19553737 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL8376356 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060074025-A1 Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability NASTECH PHARMACEUTICAL COMPANY INC. 2006-04-06 — — US disclosed
Send feedback